TOP STORIES
neurology
Multiple sclerosis

High-efficacy immunotherapies should be first line in MS: early starters have less disability


Better long-term disability outcomes in MS patients who are ‘early starters’ on high-efficacy therapies show that it is time to think the traditional escalation approach, Australian neurologists say. Patients who started induction therapy within two years of disease onset had an...

Better long-term disability outcomes in MS patients who are ‘early starters’ on high-efficacy therapies show that it is time to...

Read more